SCHEMBL6049470

SCHEMBL6049470

COCc1nc(N)nc(N)c1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.57
CYP3A4 P08684 3/20 0.57
TP53 P04637 2/20 0.57
CYP2D6 P10635 2/20 0.57
CYP2C9 P11712 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
CYP2C19 P33261 1/20 0.57
HIF1A Q16665 1/20 0.57
NCOA1 Q15788 1/20 0.51
NCOA3 Q9Y6Q9 1/20 0.51
REN P00797 1/20 0.51
DHFR P00374 2/20 0.50
HEXA P06865 2/20 0.50
HEXB P07686 2/20 0.50
MEN1 O00255 1/20 0.50
SLC22A1 O15245 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Etoprine SCHEMBL3919 0.84 DHFR (0.70) CYP1A2CYP3A4TP53CYP2D6CYP2C9
SCHEMBL14813234 0.83 CYP1A2 (0.63) CYP1A2CYP3A4TP53CYP2D6CYP2C9
SCHEMBL6049603 0.82 DHFR (0.54) CYP1A2CYP3A4TP53CYP2D6CYP2C9
SCHEMBL6049608 0.81 DHFR (0.49) CYP1A2CYP3A4TP53CYP2D6CYP2C9
SCHEMBL12377461 0.80 CYP1A2 (0.74) CYP1A2CYP3A4TP53CYP2D6CYP2C9
SCHEMBL7534201 0.80 CYP1A2 (0.62) CYP1A2CYP3A4TP53CYP2D6CYP2C9
SCHEMBL6049461 0.77 GSK3A (0.47) CYP1A2CYP3A4TP53CYP2D6CYP2C9
Metoprine SCHEMBL3681 0.76 NPC1 (0.54) CYP1A2CYP3A4TP53CYP2D6CYP2C9
Metoprine SCHEMBL29463675 0.76 NPC1 (0.54) CYP1A2CYP3A4TP53CYP2D6CYP2C9
SCHEMBL14813118 0.76 GHSR (0.60) RENDHFRHEXAHEXB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1681058-A2 Pharmacologically active cns compounds THE WELLCOME FOUNDATION LIMITED (GB) 2006-07-19 EP disclosed
EP-1325916-A1 Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system THE WELLCOME FOUNDATION LIMITED (GB) 2003-07-09 EP disclosed
US-5712276-A TREATING NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. (US) 1998-01-27 US disclosed
US-5684005-A PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE GLAXO WELLCOME INC. (US) 1997-11-04 US disclosed
US-5635507-A PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER GLAXO WELLCOME INC. (US) 1997-06-03 US disclosed
US-5597828-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY GLAXO WELLCOME INC. (US) 1997-01-28 US disclosed
US-5597827-A CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS GLAXO WELLCOME INC. 1997-01-28 US disclosed
US-5591746-A GLUTAMATE INHIBITORS; CENTRAL NERVOUS SYSTEM DISORDERS GLAXO WELLCOME INC. 1997-01-07 US disclosed
US-5587380-A ANTIISCHEMIC AGENTS GLAXO WELLCOME INC. (US) 1996-12-24 US disclosed
EP-0727214-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727213-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0727212-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP disclosed
EP-0715851-A2 Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-06-12 EP disclosed
EP-0713703-A2 Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders THE WELLCOME FOUNDATION LIMITED (GB) 1996-05-29 EP disclosed
US-5136080-A Intermediates for glutamate inhibitors BURROUGHS WELLCOME CO. (US) 1992-08-04 US disclosed
EP-0372934-A2 Pharmacologically active CNS compounds THE WELLCOME FOUNDATION LIMITED (GB) 1990-06-13 EP disclosed